{
    "Average Volume": "10,128,644",
    "Description": "Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmac\u00c3\u00a9uticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.",
    "Dividend Ex-Date": "N/A",
    "EPS": "1.49",
    "Forward Dividend": "N/A (N/A)",
    "Industry": "Biotechnology",
    "Last Updated": "2021-05-12 13:28",
    "Market Cap": "61.783B",
    "Next Earnings Date": "Aug 03, 2021 - Aug 09, 2021",
    "PE Ratio": "103.13",
    "Sector": "Healthcare",
    "Stock Type": "Company",
    "Symbol": "MRNA",
    "Website": "http://www.modernatx.com",
    "Year Range": "46.13 - 189.26"
}